Drugs / ADV2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT01010282 | Nov 2009 → Apr 2010 | dry eye syndrome | Allergan | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ADV2 | “The present study compared the efficacy, clinical safety, and acceptability of 2 multicomponent, lipid-based tear formulations (ADV1 and ADV2) to those of an existing...” PMID 25659956 ↗ Feb 2015 |
| Modality | Other / unclassified | “2 multicomponent, lipid-based tear formulations (ADV1 and ADV2)” PMID 25659956 ↗ Feb 2015 |
| Route | Topical | “1-2 drops in each eye, as needed, but at least twice daily” NCT01010282 ↗ |